Literature DB >> 2900252

Direct muscarinic cholinergic inhibition of hepatic glucose production in humans.

P J Boyle1, S B Liggett, S D Shah, P E Cryer.   

Abstract

To explore the potential role of the parasympathetic nervous system in human glucoregulatory physiology, responses to the muscarinic cholinergic agonist bethanechol (5.0 mg s.c.) and antagonist atropine (1.0 mg i.v.) were measured in normal humans. There were no changes in the plasma glucose concentration or rates of glucose production or utilization following atropine administration. After bethanechol administration there were no changes in the plasma glucose concentration or fluxes despite increments in plasma glucagon (75 +/- 7 to 103 +/- 10 pg/ml, P less than 0.02). There were no changes in insulin or C-peptide levels. To test the hypothesis that direct muscarinic inhibition of glucose production was offset by an indirect action of the agonist, specifically increased glucagon secretion with consequent stimulation of glucose production, bethanechol was administered while glucagon levels were held constant with the islet clamp technique (somatostatin infusion with insulin, glucagon and growth hormone replacement at fixed rates). Under that condition the muscarinic agonist induced a 25% decrement in the plasma glucose concentration (101 +/- 8 to 75 +/- 8 mg/dl, P less than 0.05). When compared with separate clamp control studies (with placebo rather than bethanechol injection) both the rate of glucose production and the glucose concentration were reduced (P less than 0.05) following bethanechol injection; the rate of glucose utilization was unaltered. Thus, we conclude: Withdrawal of parasympathetic tone does not appear to be an important glucoregulatory process in humans. Direct muscarinic cholinergic inhibition of hepatic glucose production occurs in humans but during generalized muscarinic activation this is offset by an indirect muscarinic action, increased glucagon secretion with consequent stimulation of glucose production. Thus, particularly if regional neuronal firing occurs, the parasympathetic nervous system may play an important role in human glucoregulatory physiology.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2900252      PMCID: PMC303533          DOI: 10.1172/JCI113617

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  A SENSITIVE DOUBLE ANTIBODY IMMUNOASSAY FOR HUMAN GROWTH HORMONE IN PLASMA.

Authors:  D S SCHALCH; M L PARKER
Journal:  Nature       Date:  1964-09-12       Impact factor: 49.962

2.  EFFECT OF ISCHEMIA ON KNOWN SUBSTRATES AND COFACTORS OF THE GLYCOLYTIC PATHWAY IN BRAIN.

Authors:  O H LOWRY; J V PASSONNEAU; F X HASSELBERGER; D W SCHULZ
Journal:  J Biol Chem       Date:  1964-01       Impact factor: 5.157

3.  Regional pancreatic concentration and in-vitro secretion of canine pancreatic polypeptide, insulin, and glucagon.

Authors:  R L Gingerich; P E Lacy; R E Chance; M G Johnson
Journal:  Diabetes       Date:  1978-02       Impact factor: 9.461

4.  Cholinergic modification of glucose-induced biphasic insulin release in vitro.

Authors:  R Sharp; S Culbert; J Cook; A Jennings; I M Burr
Journal:  J Clin Invest       Date:  1974-03       Impact factor: 14.808

5.  Plasma cortisol determination: radioimmunoassay and competitive protein binding compared.

Authors:  R W Farmer; C E Pierce
Journal:  Clin Chem       Date:  1974-04       Impact factor: 8.327

6.  Effect of vagotomy and vagal stimulation on insulin secretion.

Authors:  L A Frohman; E Z Ezdinli; R Javid
Journal:  Diabetes       Date:  1967-07       Impact factor: 9.461

7.  Glucose metabolism and plasma insulin level during epinephrine infusion in the dog.

Authors:  N Altszuler; R Steele; I Rathgeb; R C De Bodo
Journal:  Am J Physiol       Date:  1967-03

8.  Enzymic assay of glycerol, dihydroxyacetone, and glyceraldehyde.

Authors:  J K Pinter; J A Hayashi; J A Watson
Journal:  Arch Biochem Biophys       Date:  1967-08       Impact factor: 4.013

9.  Hormone-fuel interrelationships during fasting.

Authors:  G F Cahill; M G Herrera; A P Morgan; J S Soeldner; J Steinke; P L Levy; G A Reichard; D M Kipnis
Journal:  J Clin Invest       Date:  1966-11       Impact factor: 14.808

10.  Determination of free and total insulin and C-peptide in insulin-treated diabetics.

Authors:  H Kuzuya; P M Blix; D L Horwitz; D F Steiner; A H Rubenstein
Journal:  Diabetes       Date:  1977-01       Impact factor: 9.461

View more
  9 in total

1.  Oesophageal dysmotility, delayed gastric emptying and autonomic neuropathy correlate to disturbed glucose homeostasis.

Authors:  B Ohlsson; O Melander; O Thorsson; R Olsson; O Ekberg; G Sundkvist
Journal:  Diabetologia       Date:  2006-07-11       Impact factor: 10.122

Review 2.  Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.

Authors:  Karen L Teff; Sangwon F Kim
Journal:  Physiol Behav       Date:  2011-06-12

3.  Partial blockade of nicotinic acetylcholine receptors improves the counterregulatory response to hypoglycemia in recurrently hypoglycemic rats.

Authors:  Edmund F LaGamma; Necla Kirtok; Owen Chan; Bistra B Nankova
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-12       Impact factor: 4.310

4.  Respiratory sinus arrhythmia and diseases of aging: obesity, diabetes mellitus, and hypertension.

Authors:  Christopher M Masi; Louise C Hawkley; Edith M Rickett; John T Cacioppo
Journal:  Biol Psychol       Date:  2006-10-10       Impact factor: 3.251

5.  Cephalic phase pancreatic polypeptide responses to liquid and solid stimuli in humans.

Authors:  Karen L Teff
Journal:  Physiol Behav       Date:  2009-11-26

6.  Interrelationships among measures of autonomic activity and cardiovascular risk factors during orthostasis and the oral glucose tolerance test.

Authors:  E Peles; D S Goldstein; S Akselrod; H Nitzan; M Azaria; S Almog; D Dolphin; H Halkin; M Modan
Journal:  Clin Auton Res       Date:  1995-10       Impact factor: 4.435

7.  Diminished brain glucose metabolism is a significant determinant for falling rates of systemic glucose utilization during sleep in normal humans.

Authors:  P J Boyle; J C Scott; A J Krentz; R J Nagy; E Comstock; C Hoffman
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

8.  Constant hepatic ATP concentrations during prolonged fasting and absence of effects of Cerbomed Nemos® on parasympathetic tone and hepatic energy metabolism.

Authors:  Sofiya Gancheva; Alessandra Bierwagen; Daniel F Markgraf; Gidon J Bönhof; Kevin G Murphy; Erifili Hatziagelaki; Jesper Lundbom; Dan Ziegler; Michael Roden
Journal:  Mol Metab       Date:  2017-10-25       Impact factor: 7.422

9.  Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance.

Authors:  Songyan Wang; Lauren Z Oestricker; Michael J Wallendorf; Karin Sterl; Judit Dunai; C Rachel Kilpatrick; Bruce W Patterson; Dominic N Reeds; Burton M Wice
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.